keyword
MENU ▼
Read by QxMD icon Read
search

Lucentis

keyword
https://www.readbyqxmd.com/read/28919773/sickle-cell-retinopathy-improving-care-with-a-multidisciplinary-approach
#1
REVIEW
Farid Menaa, Barkat Ali Khan, Bushra Uzair, Abder Menaa
Sickle cell retinopathy (SCR) is the most representative ophthalmologic complication of sickle cell disease (SCD), a hemoglobinopathy affecting both adults and children. SCR presents a wide spectrum of manifestations and may even lead to irreversible vision loss if not properly diagnosed and treated at the earliest. Over the past decade, multidisciplinary research developments have focused upon systemic, genetic, and ocular risk factors of SCR, enabling the clinician to better diagnose and manage these patients...
2017: Journal of Multidisciplinary Healthcare
https://www.readbyqxmd.com/read/28846476/identification-of-multiple-serine-to-asparagine-sequence-variation-sites-in-an-intended-copy-product-of-lucentis%C3%A2-by-mass-spectrometry
#2
François Griaud, Andrej Winter, Blandine Denefeld, Manuel Lang, Héloïse Hensinger, Frank Straube, Mirko Sackewitz, Matthias Berg
Patent expiration of first-generation biological and the high cost of innovative biological are 2 drivers for the development of biosimilar products. There are, however, technical challenges to the production of exact copies of such large molecules. In this study, we performed a head-to-head comparison between the originator anti-VEGF-A Fab product LUCENTIS® (ranibizumab) and an intended copy product using an integrated analytical approach. While no differences could be observed using size-exclusion chromatography, capillary electrophoresis-sodium dodecyl sulfate and potency assays, different acidic peaks were identified with cation ion exchange chromatography and capillary zone electrophoresis...
August 28, 2017: MAbs
https://www.readbyqxmd.com/read/28845845/lucentis-%C3%A2-ranibizumab-abbreviated-uk-prescribing-information
#3
(no author information available yet)
No abstract text is available yet for this article.
August 2017: Eye
https://www.readbyqxmd.com/read/28809980/stimuli-responsive-nlo-properties-of-tetrathiafulvalene-fused-donor-acceptor-chromophores
#4
E Cariati, X Liu, Y Geng, A Forni, E Lucenti, S Righetto, S Decurtins, S-X Liu
The second-order nonlinear optical (NLO) properties of two tetrathiafulvalene (TTF)-fused electron donor-acceptor dyads have been determined using the Electric Field Induced Second Harmonic generation (EFISH) technique and theoretically rationalized. Dyads TTF-dppz (1) and TTF-BTD (2) were obtained by direct fusion of a TTF electron donor unit either with a dipyrido[3,2-a:2',3'-c]phenazine (dppz) or a benzothiadiazole (BTD) electron acceptor moiety. Dyad 1 acts as a reversible acido-triggered NLO switch by protonation/deprotonation at two nitrogen atoms of the dppz acceptor moiety induced by sequential exposure to HCl and ammonia vapors...
August 23, 2017: Physical Chemistry Chemical Physics: PCCP
https://www.readbyqxmd.com/read/28736371/-multifocal-electroretinography-for-therapeutic-effect-evaluation-of-intravitreal-injection-lucentis-for-wet-age-related-macular-degeneration
#5
Rui-Hong Ju, Man-Sha He, Jin-Tong Hou, Meng-Yuan Li, Jing-Lin Zhang, Zhe-Ming Wu
OBJECTIVE: To evaluate the changes in retinal functions using multifocal electroretinography (mfERG) following intravitreal injection of Lucentis for treatment of wet age-related macular degeneration. METHODS: This prospective study was conducted in 14 patients (9 men and 5 women, 14 eyes) with wet age-related macular degeneration receiving treatment with intravitreal injections of ranibizumab (Lucentis) in our hospital between October, 2014 and January, 2016. All the patients received the treatment following a 1+PRN protocol and after the initial injection, the patients were followed up monthly for 6 months to decide if additional injections were needed...
July 20, 2017: Nan Fang Yi Ke da Xue Xue Bao, Journal of Southern Medical University
https://www.readbyqxmd.com/read/28654629/predictors-of-one-year-visual-outcomes-after-anti-vascular-endothelial-growth-factor-treatment-for-neovascular-age-related-macular-degeneration
#6
Laurent Kodjikian, Evelyne Decullier, Eric H Souied, Adeline Roux, Gilles Aulagner, Laure Huot
PURPOSE: To determine predictors of best-corrected visual acuity (BCVA) outcomes 1 year after ranibizumab or bevacizumab treatment for neovascular age-related macular degeneration, within the French Study Group Avastin versus Lucentis for neovascular age-related macular degeneration (GEFAL). METHODS: Patients aged ≥50 years presenting subfoveal neovascular age-related macular degeneration were randomized to receive ranibizumab or bevacizumab (3 monthly intravitreal injections followed by an as-needed regimen)...
June 20, 2017: Retina
https://www.readbyqxmd.com/read/28613352/comparison-of-ranibizumab-and-bevacizumab-for-macular-edema-secondary-to-retinal-vein-occlusions-in-routine-clinical-practice
#7
Mehnaz Khan, Karen M Wai, Fabiana Q Silva, Sunil Srivastava, Justis P Ehlers, Aleksandra Rachitskaya, Amy Babiuch, Ryan Deasy, Peter K Kaiser, Andrew P Schachat, Alex Yuan, Rishi P Singh
BACKGROUND AND OBJECTIVE: To determine outcomes of intravitreal ranibizumab (IVR) (Lucentis; Genentech, South San Francisco, CA) versus bevacizumab (IVB) (Avastin; Genentech, South San Francisco, CA) for treatment of macular edema (ME) secondary to retinal vein occlusion (RVO) in routine clinical practice. PATIENTS AND METHODS: A retrospective study identified treatment-naïve patients with ME secondary to RVO where treatment with either IVB or IVR was initiated...
June 1, 2017: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/28613220/optical-coherence-tomography-baseline-predictors-for-initial-best-corrected-visual-acuity-response-to-intravitreal-anti-vascular-endothelial-growth-factor-treatment-in-eyes-with-diabetic-macular-edema-the-chartres-study
#8
Ana R Santos, Miguel  Costa, Christian Schwartz, Dalila Alves, João Figueira, Rufino Silva, Jose G Cunha-Vaz
PURPOSE: To identify baseline optical coherence tomography morphologic characteristics predicting the visual response to anti-vascular endothelial growth factor therapy in diabetic macular edema. METHODS: Sixty-seven patients with diabetic macular edema completed a prospective, observational study (NCT01947881-CHARTRES). All patients received monthly intravitreal injections of Lucentis for 3 months followed by PRN treatment and underwent best-corrected visual acuity measurements and spectral domain optical coherence tomography at Baseline, Months 1, 2, 3, and 6...
May 2, 2017: Retina
https://www.readbyqxmd.com/read/28499055/sequential-sterile-intraocular-inflammation-associated-with-consecutive-intravitreal-injections-of-aflibercept-and-ranibizumab
#9
Dilraj S Grewal, Tayler Schwartz, Sharon Fekrat
The authors report the unique response of two patients treated for cystoid macular edema (CME) secondary to central retinal vein occlusion (CRVO) who developed sequential episodes of likely sterile inflammatory responses following separate intravitreal injections of aflibercept (Eylea; Regeneron, Tarrytown, NY) and ranibizumab (Lucentis; Genentech, South San Francisco, CA) despite multiple previous uneventful injections for CME secondary to CRVO. Following the twenty-fifth aflibercept and seventh ranibizumab injection, two patients developed an acute inflammatory response, which was treated empirically with intravitreal antibiotics and topical and oral steroids (in Case 2)...
May 1, 2017: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/28498374/ranibizumab-pretreatment-in-diabetic-vitrectomy-a-pilot-randomised-controlled-trial-the-radivit-study
#10
O Comyn, L Wickham, D G Charteris, P M Sullivan, E Ezra, Z Gregor, G W Aylward, L da Cruz, D Fabinyi, T Peto, M Restori, W Xing, C Bunce, P G Hykin, J W Bainbridge
PurposeOur aim was to evaluate the impact of intravitreal ranibizumab pretreatment on the outcome of vitrectomy surgery for advanced proliferative diabetic retinopathy. The objective was to determine the feasibility of a subsequent definitive trial and estimate the effect size and variability of the outcome measure.Patients and methodsWe performed a pilot randomised double-masked single-centre clinical trial in 30 participants with tractional retinal detachment associated with proliferative diabetic retinopathy...
September 2017: Eye
https://www.readbyqxmd.com/read/28482126/cytosolic-expression-of-functional-fab-fragments-in-e-coli-using-a-novel-combination-of-dual-sumo-expression-cassette-and-enbase-%C3%A2-cultivation-mode
#11
Faegheh Rezaie, Fatemeh Davami, Kamran Mansouri, Sulmaz Agha Amiri, Ramin Fazel, Reza Mahdian, Noushin Davoudi, Somayeh Enayati, Mohammad Azizi, Vahid Khalaj
AIMS: The E. coli expression system is highly effective in producing recombinant proteins. However, there are some limitations in this system, especially in obtaining correctly folded forms of some complex proteins such as Fab fragments. To improve the solubility and folding quality of Fab fragments, we have examined the effect of simultaneous application of a SUMO fusion tag, EnBase(®) cultivation mode and a redox mutant strain in the E. coli expression system. METHODS AND RESULTS: A bicistronic gene construct was designed to express an anti-VEGF Fab fragment as a model system...
May 8, 2017: Journal of Applied Microbiology
https://www.readbyqxmd.com/read/28458510/evaluation-of-contrast-sensitivity-and-other-visual-function-outcomes-in-neovascular-age-related-macular-degeneration-patients-after-treatment-switch-to-aflibercept-from-ranibizumab
#12
Donald R Nixon, Nicholas Ap Flinn
PURPOSE: This study evaluated visual function and anatomic and vision-related quality-of-life outcomes in recalcitrant neovascular age-related macular degeneration (AMD) subjects switched to aflibercept (Eylea(®)) from ranibizumab (Lucentis(®)). METHODS: In a single-center study conducted in Barrie, ON, 40 patients with persistent fluid despite previous ranibizumab treatment were switched to aflibercept with 3 consecutive monthly doses. Main outcome measure was mean change from baseline to week 12 in Pelli-Robson contrast sensitivity (CS)...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/28442372/long-term-release-and-stability-of-pharmaceutical-proteins-delivered-from-solid-lipid-implants
#13
Moritz Vollrath, Julia Engert, Gerhard Winter
Solid lipid implants (SLIs) prepared by twin-screw (tsc) extrusion represent a promising technology platform for the sustained release of pharmaceutical proteins. In this work, we report on two aspects, long-term release and stability of released protein. First, SLIs were produced by tsc-extrusion containing the low melting triglyceride H12 and the high melting triglyceride Dynasan D118. Two different proteins available in a freeze-dried matrix containing hydroxypropyl-β-cyclodextrine (HP-β-CD) were incorporated into the lipid matrix: a monoclonal antibody (mAb) from the IgG1 class and the fab-fragment Ranibizumab (Lucentis(®))...
April 22, 2017: European Journal of Pharmaceutics and Biopharmaceutics
https://www.readbyqxmd.com/read/28435212/testing-the-clinical-value-of-multifocal-electroretinography-and-microperimetry-and-the-effects-of-intravitreal-therapy-with-ranibizumab-on-macular-function-in-the-course-of-wet-age-related-macular-degeneration-a-1-year-prospective-study
#14
Mihaela Reinsberg, Ralf-Dieter Hilgers, Inger Lüdeke, Khaled Nassar, Swaantje Grisanti, Salvatore Grisanti, Julia Lüke, Matthias Lüke
PURPOSE: To investigate the clinical value of multifocal electroretinography (mfERG) and microperimetry and the effects of intravitreal therapy with ranibizumab (Lucentis(®)) on macular function in the course of neovascular age-related macular degeneration (nAMD). MATERIALS AND METHODS: We conducted a prospective single-arm interventional cohort study with 20 nAMD patients older than 50 years. Examinations were scheduled monthly for 1 year during intravitreal therapy with ranibizumab...
2017: Clinical Ophthalmology
https://www.readbyqxmd.com/read/28419398/pre-existing-rpe-atrophy-and-defects-in-the-external-limiting-membrane-predict-early-poor-visual-response-to-ranibizumab-in-neovascular-age-related-macular-degeneration
#15
RANDOMIZED CONTROLLED TRIAL
Souska Zandi, Florian Weisskopf, Justus G Garweg, Isabel B Pfister, Christian Pruente, Florian Sutter, Katja Hatz
BACKGROUND AND OBJECTIVES: The aim of this study was to identify the rate of early visual acuity poor responders in patients with neovascular age-related macular degeneration (AMD) after the first intravitreal injection of ranibizumab (Lucentis; Genentech, South San Francisco, CA) and to determine potential predictors for early response. PATIENTS AND METHODS: Patients with choroidal neovascularization secondary to AMD were evaluated before and 1 month after their first ranibizumab treatment...
April 1, 2017: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/28405488/multiple-intravitreal-ranibizumab-injections-for-persistant-choroidal-neovascularization-associated-with-presumed-ocular-histoplasmosis-syndrome
#16
Turgut Yılmaz, Seyhan Dikci, Oğuzhan Genç, Kayhan Mutlu
Presumed ocular histoplasmosis syndrome (POHS) is a clinical entity that is characterized by small, round, discrete, macular or mid peripheral atrophic (punched out) chorioretinal lesions (histo spots), peripapillary scarring, choroidal neovascularization (CNV), and the absence of anterior uveitis and vitritis. Diagnosis of this disorder is based upon characteristic clinical findings and a positive histoplasmin skin test or residence in an endemic region for Histoplasma capsulatum. There is no active systemic disease during diagnosis of POHS...
April 2017: Turkish Journal of Ophthalmology
https://www.readbyqxmd.com/read/28399772/nurse-led-ranibizumab-intravitreal-injections-in-wet-age-related-macular-degeneration-a-literature-review
#17
Emma Gregg
Aim The aim of this literature review was to explore the development of the role of specialist ophthalmic nurses in delivering ranibizumab intravitreal injections to patients with wet age-related macular degeneration (AMD), and to evaluate their contribution to reducing capacity pressures in medical retina services, while maintaining safe and effective standards of care. Method A systematic literature search was undertaken to identify relevant articles published between January 2000 and June 2015. A search of electronic databases was undertaken, and selected relevant journals were searched manually...
April 12, 2017: Nursing Standard
https://www.readbyqxmd.com/read/28388077/h-aggregates-granting-crystallization-induced-emissive-behavior-and-ultralong-phosphorescence-from-a-pure-organic-molecule
#18
Elena Lucenti, Alessandra Forni, Chiara Botta, Lucia Carlucci, Clelia Giannini, Daniele Marinotto, Andrea Previtali, Stefania Righetto, Elena Cariati
Solid-state luminescent materials with long lifetimes are the subject of ever-growing interest from both a scientific and a technological point of view. However, when dealing with organic compounds, the achievement of highly efficient materials is limited by aggregation-caused quenching (ACQ) phenomena on one side and by ultrafast deactivation of the excited states on the other. Here, we report on a simple organic molecule, namely, cyclic triimidazole (C9H6N6), 1, showing crystallization-induced emissive (CIE) behavior and, in particular, ultralong phosphorescence due to strong coupling in H-aggregated molecules...
April 20, 2017: Journal of Physical Chemistry Letters
https://www.readbyqxmd.com/read/28334720/intravitreal-dexamethasone-implant-versus-intravitreal-ranibizumab-for-the-treatment-of-macular-edema-secondary-to-retinal-vein-occlusion-in-a-chinese-population
#19
Xiaoya Gu, Xiaobing Yu, Shuang Song, Hong Dai
BACKGROUND: The aim of this work was to compare the efficacy of intravitreal dexamethasone implant (Ozurdex) and intravitreal ranibizumab (Lucentis) in the treatment of macular edema (ME) caused by retinal vein occlusion (RVO). METHODS: Thirty-two ME cases treated with Ozurdex and 32 ME cases treated with ranibizumab were enrolled, with 26 central (C)RVO and 6 branch (B)RVO subjects in each group. We compared the results of best-corrected visual acuity (BCVA), central retinal thickness, number of injections, and intraocular pressure (IOP) at 1, 2, 3, and 6 months after injection...
2017: Ophthalmic Research
https://www.readbyqxmd.com/read/28297035/short-term-effects-of-early-switching-to-ranibizumab-or-aflibercept-in-diabetic-macular-edema-cases-with-non-response-to-bevacizumab
#20
Mohammed Ashraf, Ahmed A R Souka, Hassan ElKayal
BACKGROUND AND OBJECTIVES: To study the effect of early switching to ranibizumab (Lucentis; Genentech, South San Francisco, CA) or aflibercept (Eylea; Regeneron, Tarrytown, NY) in cases of diabetic macular edema (DME) that have shown no response to bevacizumab (Avastin; Genentech, South San Francisco, CA). PATIENTS AND METHODS: A retrospective study involving 59 eyes of 45 patients with DME previously treated with bevacizumab. Patients were switched either to ranibizumab or aflibercept...
March 1, 2017: Ophthalmic Surgery, Lasers & Imaging Retina
keyword
keyword
1765
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"